Apr 11th, 2013 | |
Launch of semi-synthetic artemisinin a milestone for malaria, synthetic biology |
|
(Nanowerk News) Twelve years after a breakthrough discovery in his University of California, Berkeley, laboratory, professor of chemical engineering Jay Keasling is seeing his dream come true. | |
On April 11, the pharmaceutical company Sanofi will launch the large-scale production of a partially synthetic version of artemisinin, a chemical critical to making today’s front-line antimalaria drug, based on Keasling’s discovery.read more at nanowerk
http://www.nanowerk.com/news2/biotech/newsid=29955.php The “semi-synthetic” artemisinin is chemically modified to an active drug, such as artesunate, and combined in ACT with another antimalarial drug to lessen the chance that the malaria parasite will develop resistance to artemisinin. Sanofi plans to produce 35 tons of artemisinin in 2013 and, on average, 50 to 60 tons a year by 2014, which will translate to between 80 and 150 million ACT treatments. Sweet wormwood was used in ancient Chinese therapy to treat various illnesses, including fevers typical of malaria. In the 1970s, Chinese scientists rediscovered it and identified its active ingredient, artemisinin, and artemisinin is now extracted from sweet wormwood grown commercially in China, Southeast Asia and Africa. The quality, supply and cost have been unpredictable and inconsistent, however. Keasling’s goal was to create a synthetic version with a stable and ideally lower price that could be produced in sufficient quantity to treat the 300-500 million cases of malaria that arise each year. Sanofi and OneWorld Health, the not-for-profit drug development affiliate of the Program for Appropriate Technology in Health (PATH), have launched a commercial-scale production line for semisynthetic artemisinin, a move they say is “a pivotal milestone in the fight against malaria”. Global demand for artemisinin is the most effective malaria treatment available but the existing botanical supply – which is derived from the sweet wormwood plant – is inconsistent. Therefore, Sanofi says that having “multiple sources of high-quality artemisinin will strengthen the artemisinin supply chain, contribute to a more stable price and ultimately ensure greater availability of treatment”. The company notes that the production line at its facility in Garessio, Italy, will be able to produce enough artemisinin, using technology developed by US firm Amyris, for around 80-150 million artemisinin-based combination therapies by 2014. |
Launch of semi-synthetic artemisinin a milestone for malaria, synthetic biology
SEARCH THIS BLOG

ORGANIC SPECTROSCOPY

Pages
- About me
- All about drugs
- Bioavailability
- CLINICAL TRIALS
- Combinatorial Chemistry in Drug Design
- DISCLAIMER
- Drug Basics
- DRUG COMPANIES
- DRUG DESIGN
- DRUG DISCOVERY
- Drug Information
- DRUG NEWS
- DRUG PORTALS
- Drug resistance
- DRUG SITES
- DRUG SYNTHESIS
- DRUGS NDA
- DRUGS, FDA2012
- FDA -US
- GMP
- HEALTH CANADA
- HELP ME/ ACCOLADES
- HSA SINGAPORE
- INDA
- KOREA DRUG APPROVAL PROCESS
- MHLW JAPAN, 厚生労働省
- NMPA CHINA
- PATENT EXPIRY DATES 1/3
- PATENT EXPIRY DATES 2/3
- PATENT EXPIRY DATES 3/3
- Patent portals
- Polymorphism
- Regulations and Guidance
- Scientificupdate (UK) on a roll
- sFDA CHINA
- SOUTH AFRICA, MCC
- SPECIAL DRUGS
- Traditional Medicine
- WHAT IS A DRUG
- World drug tracker
Archives
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
Categories
- 0rphan drug status
- 2020 APPROVALS
- accelerated approval
- Acute Hepatic Porphyria
- Acute myeloid leukaemia
- African medicine
- AIDS
- Alzheimer's
- ANAESTHETIC
- anaesthetics
- analgesic
- ANALYTICAL
- ANDA
- Anthony crasto
- ANTI ACNE
- ANTI DIABETES
- ANTI FUNGAL
- ANTI INFLAMATORY
- anti tubeculosis
- antibacterial
- Antibiotics
- ANTIBODIES
- ANTICONVULSANT
- Antiemetic
- antiglaucoma
- Antihypertensives
- antiinfluenza
- antimalarials
- Antineoplastic
- antiobesity
- Antispasmodic
- ANTITUSSIVE
- Antiulcerative
- Antivirals
- APPROVALS 2021
- APPROVALS 2022
- ARAB MEDICINE
- Atopic dermatitis
- Australia
- AUSTRALIA 2021
- AWARD
- AYURVEDA
- Biosimilar drugs
- BLA
- BLOGS
- Breakthrough Therapy Designation
- canada
- CANADA 2021
- cancer
- cfda
- CHINA 2011
- CHINA 2012
- CHINA 2018
- china 2019
- china pipeline
- CHINESE HERBS
- chronic kidney disease
- CLINICAL TRIALS
- COMPANIES
- conference
- Contrast agent
- CORONAVIRUS
- COVID-19
- CRL
- CYSTIC FIBRIOSIS
- Dengue
- DIABETES
- DNDi
- Drug discovery
- DRUG MARKETING
- DRUG REVIEW
- Duchenne muscular dystrophy
- EMA
- EU 2003
- EU 2005
- EU 2014
- EU 2015
- EU 2016
- EU 2017
- EU 2018
- EU 2020
- EU 2021
- EU 2022
- EU PIPELINE
- EU SUBMISSION
- EXTENDED USE
- FAST TRACK FDA
- FDA 15
- FDA 2010
- FDA 2011
- FDA 2012
- FDA 2013
- FDA 2014
- FDA 2015
- FDA 2016
- FDA 2017
- FDA 2018
- FDA 2019
- FDA 2020
- fda 2021
- FDA 2022
- Featured product
- female sexual dysfunction
- FIBROMYGALIA
- flow synthesis
- FORMULATION
- GAIN
- Gastric Proton Pump Inhibitor
- Generating Antibiotic Incentives Now
- GENERIC DRUG
- GENERICS
- glenmark
- GLENMARK
- GLIPTIN
- GMP
- gout
- Greek medicine
- hepatitis C viral infections
- Herbals
- HOMEOPATHY
- HORMONE
- Human medicines European Public Assessment Report EPAR
- Hypertension
- hypnotic
- idiopathic pulmonary fibrosis
- IMPLANTS
- IND
- IND 2017
- IND 2018
- IND 2021
- IND Filed
- INDIA 2020
- INDIA 2022
- Insomnia
- Investigational device exemption (IDE) approval
- JAPAN 2009
- JAPAN 2013
- JAPAN 2014
- JAPAN 2015
- JAPAN 2016
- japan 2017
- JAPAN 2018
- japan 2019
- japan 2020
- JAPAN 2021
- JAPAN 2022
- Japan marketing
- Japan pipeline
- Korea
- korea 2012
- korea 2016
- korea 2019
- Lactams
- MAA
- Macrolides
- Malaria
- MANUFACTURING
- Market info
- Marketing authorisation application EU
- MEDICAL DEVICE
- MIGRAINE
- molybdenum cofactor deficiency
- Monoclonal antibody
- Nanotechnology
- NCE
- NDA
- NDA JAPAN
- neuropathic pain
- Neutraceuticals
- New Drug Application Resubmission FDA
- NEW DRUGS
- New drugs canada
- New drugs china
- New drugs EU
- New drugs Japan
- NEW USE DRUGS
- Newzealand
- NICE
- non-Hodgkin's lymphoma
- NUCLEOTIDES
- obesity
- OCCULAR
- ocular hypertension
- organic chemistry
- osteoarthritis
- PAIN
- Parkinson's disease
- PATENT
- PATENTS
- Peptide drugs
- PFIZER
- PHASE 1
- PHASE 3
- PHASE1
- Phase2 drugs
- Phase3 drugs
- plaque psoriasis
- POLYMORPH
- Preclinical china
- Preclinical drugs
- Premture ejaculation
- prime designation
- Priority review
- PROCESS
- Promising clips
- Psoriasis
- QbD
- QIDP
- radio labelled
- RADIOACTIVE AGENT
- RADIOLABELLED
- Rare disease
- RARE PEDIATRIC DISEASE REVIEW
- Regenerative medicine
- Regulatory
- Resubmission FDA
- REVIEW
- rheumatoid arthritis
- SCHLEROSING AGENT
- Scottish Medicines Consortium
- sex arousal
- SFDA FAST TRACK
- SINGAPORE
- sNDA
- sNDA JAPAN
- Solid tumours
- spectroscopy
- SPOTLIGHT
- Stem cells
- SYNTHESIS
- TIVE
- TOXINS
- Translational medicine
- Transverse myletis
- Tropical Disease Priority Review Voucher
- UK
- UNANI MEDICINE
- Uncategorized
- US HERBS
- USFDA SUBMISSION
- vaccine
- veterinary
- virus
- VITAMINS
- x ray contrast agent
Recent Posts
- Darinaparsin June 28, 2022
- Pimitespib June 26, 2022
- VP1-001 June 20, 2022
- Vutrisiran sodium, ALN 65492, Votrisiran June 17, 2022
- DIFLUPREDNATE June 13, 2022
- COBITOLIMOD June 8, 2022
- Dr. D Srinivasa Reddy appointed Director CSIR-IICT Hyderabad India on 7th June 2022. A new assignment June 8, 2022
- ARIMOCLOMOL May 30, 2022
- IMIPRIDONE May 20, 2022
- Tirzepatide May 18, 2022
Blog Stats
- 3,948,931 hits
Top Clicks
Top Posts & Pages
- Oat Straw (Avena sativa) helpful in calming the nerves of those who are detoxing from drug or alcohol addiction, and can even help curb nicotine cravings.
- होम्योपैथिक दवा ; मूलेन आयल ; कान के सभी रोगों की अचूक और सटीक दवा ; MULLEIN OIL ; THE HOMOEOPATHIC REMEDIY FOR ALL "EAR" DISORDERS ; THE MOST SAFEST NATURAL REMEDY
- Tegoprazan
- Lisdexamphetamine
- PATENT EXPIRY DATES 1/3
- CITICOLINE
- PATENT EXPIRY DATES 2/3
- DEUCRAVACITINIB
- Garcinia Cambogia Kills 89% of Pancreatic Cancer Cells and Synergizes with Curcumin
- Enavogliflozin, DWP-16001
Recent Comments
SEARCH THIS BLOG
3 Comments
Leave a Reply Cancel reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
DR ANTHONY CRASTO
Pages
- About me
- All about drugs
- Bioavailability
- CLINICAL TRIALS
- Combinatorial Chemistry in Drug Design
- DISCLAIMER
- Drug Basics
- DRUG COMPANIES
- DRUG DESIGN
- DRUG DISCOVERY
- Drug Information
- DRUG NEWS
- DRUG PORTALS
- Drug resistance
- DRUG SITES
- DRUG SYNTHESIS
- DRUGS NDA
- DRUGS, FDA2012
- FDA -US
- GMP
- HEALTH CANADA
- HELP ME/ ACCOLADES
- HSA SINGAPORE
- INDA
- KOREA DRUG APPROVAL PROCESS
- MHLW JAPAN, 厚生労働省
- NMPA CHINA
- PATENT EXPIRY DATES 1/3
- PATENT EXPIRY DATES 2/3
- PATENT EXPIRY DATES 3/3
- Patent portals
- Polymorphism
- Regulations and Guidance
- Scientificupdate (UK) on a roll
- sFDA CHINA
- SOUTH AFRICA, MCC
- SPECIAL DRUGS
- Traditional Medicine
- WHAT IS A DRUG
- World drug tracker
Latest Posts
-
Darinaparsin
SVG Image IUPAC Condensed H-gGlu-Cys(Unk)-Gly-OH Sequence XXG Darinaparsin ダリナパルシン , Darvias JAPAN 2022 APPROVED, PMDA 2022/6/20 (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-dimethylarsanylsulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid (S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((dimethylarsino)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid Glycine, L-gamma-glutaMyl-S-(diMethylarsino)-L-cysteinyl- Formula C12H22AsN3O6S CAS 69819-86-9 Mol…
-
Pimitespib
Pimitespib TAS 116 CAS 1260533-36-5 Antineoplastic, Hsp 90 inhibitor 3-ethyl-4-[4-[4-(1-methylpyrazol-4-yl)imidazol-1-yl]-3-propan-2-ylpyrazolo[3,4-b]pyridin-1-yl]benzamide Pimitespib (TAS-116) is an oral bioavailable, ATP-competitive, highly specific HSP90α/HSP90β inhibitor (Kis of 34.7 nM and 21.3 nM, respectively)…
-
VP1-001
VP1-001 CAS 2140-46-7 Cholest-5-ene-3,25-diol, (3β)-Molecular Weight, 402.65, C27 H46 O2 Cholest-5-ene-3β,25-diol (8CI) (3β)-Cholest-5-ene-3,25-diol 25-Hydroxy-5-cholestene-3β-ol 25-Hydroxycholesterol 5-Cholesten-3β,25-diol Compound 29 – ViewPoint Therapeutics Originator University of California at San Francisco;…
-
Vutrisiran sodium, ALN 65492, Votrisiran
RNA, (Um-sp-(2′-deoxy-2′-fluoro)C-sp-Um-Um-Gm-(2′-deoxy-2′-fluoro)G-Um-Um-(2′-deoxy-2′-fluoro)A-Cm-Am-Um-Gm-(2′-deoxy-2′-fluoro)A-Am-(2′-deoxy-2′-fluoro)A-Um-Cm-Cm-Cm-Am-sp-Um-sp-Cm), complex with RNA (Um-sp-Gm-sp-Gm-Gm-Am-Um-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)A-(2′-deoxy-2′-fluoro)U-Gm-Um-Am-Am-Cm-Cm-Am-Am-Gm-Am) 3′-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate] (1:1) Vutrisiran Sodium Nucleic Acid Sequence Sequence Length: 44, 23, 2113 a 9 c 8 g…
DR ANTHONY MELVIN CRASTO Ph.D
DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK LIFE SCIENCES LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 30 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, Dr T.V. Radhakrishnan and Dr B. K. Kulkarni, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 30 PLUS year tenure till date June 2021, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 90 Lakh plus views on dozen plus blogs, 233 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 33 lakh plus views on New Drug Approvals Blog in 233 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc
Personal Links
- my sites on the net
- DR ANTHONY MELVIN CRASTO
- GOOGLE GROUP ORGANIC PROCESS DEVELOPMENT
- mixxt
- epernicus
- scipeople
- jimdo
- yolasite
- my cv
- slidestaxx
- wordpress blog
- ABOUT ME
- BRANDSITE
- SKILLPAGES
- Academia.edu
- DIIGO
- WIX
- WIX BLOG
- ISSUU
- SCRIBD
- BIZ
- GOOGLE BLOG
- APNACIRCLE
- Eurekamoments in Organic Chemistry
- Organic Chemistry by Dr Anthony
- Green Chemistry International
- Technology Transfer
- Stereochemistry
- Spectroscopy
- Polymorphism
- Reactions in Org Chem
- DR ANTHONY MELVIN CRASTO Ph.D
- Pharmaceuticals
- Medicinal chemistry
- Organic chemistry literature
- Patent related site
- Green chemistry
- Reagents
- R & D
- Molecules
- Heterocyclic chem
- Sourcing
- NEW DRUG APPROVALS
- WORLD DRUG TRACKER
- Green Chemistry International
- drug regulatory affairs international
- ORGANIC SPECTROSCOPY INTERNATIONAL
- ORGANIC SYNTHESIS INTERNATIONAL
- ALL ABOUT DRUGS
- ORGANIC CHEMISTRY INTERNATIONAL
- GOOGLE PLUS
- Drug Scaleup and Manufacturing International
- MEDICINAL CHEMISTRY INTERNATIONAL
- DRUG SYNTHESIS INTERNATIONAL
- SLIDESHARE
- DRUGS WEB
- GOOGLE SCHOLAR
- MEDCHEM-amcrasto
- ONE ORGANIC CHEMISTONE DAY
- DRUG PATENTS INTERNATIONAL
- MEDCHEM ANTHONY CRASTO
- MEDCHEM anthony crasto
- Gravatar
- ZING ME VIETNAM
- RESEARCH GATE
- AWARDS
Recent Comments
- Memory Worlddrugtracker 7 th July 2017 Receiving Best Worlddrugtracker Award for lifetime acheivement in Pharma… twitter.com/i/web/status/1… 2 hours ago
- memory Conferred prestigious individual national award at function for contribution to pharma society from Times N… twitter.com/i/web/status/1… 2 days ago
- GSK 2330672, LINERIXIBAT newdrugapprovals.org/2017/07/21/gsk… via @amcrasto 4 days ago
- @csiriict twitter.com/csiriict/statu… 4 days ago
- @DSReddy_IIIM @CSIR_IND @csir_ncl @CSIR_CDRI @csiriiim twitter.com/csiriict/statu… 4 days ago
- RT @csiriiim: National #Conference on “Recent trends in Plant Biology” from 5-7 Sept at @csiriiim. iiim.res.in🅽🅴🆆👉national-con… 4 days ago
- fitchratings.com/research/corpo… 5 days ago
- livemint.com/companies/news… 5 days ago
- Glenmark Pharmaceuticals acquires certain OTC drugs from Wockhardt in US mybs.in/2awPXOR 5 days ago
- indiainfoline.com/article/news-t… 5 days ago
- Glenmark gets CDSCO Panel nod to study antidiabetic FDC containing Dapagliflozin, Sitagliptin, Metformin medicaldialogues.in/news/industry/… 5 days ago
- RT @carbanio: When you register with Carbanio as a Seller, Whole of India * can see your Chemicals * speak about your Chemicals * listen… 1 week ago
- RT @CSIR_CDRI: #सीएसआईआर_सीडीआरआई #लखनऊ में #जिज्ञासा कार्यक्रम के अन्तर्गत छात्र-वैज्ञानिक संयोजन कार्यक्रम में #ज़ी_कॉलेज_ऑफ_फ़ार्मेसी #उ… 1 week ago
- Darinaparsin newdrugapprovals.org/2022/06/28/dar… via @amcrasto 1 week ago
That’s indeed a great milestone to share, this discovery will be of immense use
Reblogged this on medchemnintabelle.
Reblogged this on Srilanka-Chem.